Has Nathan Zasler received payments from drug or device companies?

Yes. Drug and device makers reported $1,371 in general payments to Nathan Zasler across 75 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nathan Zasler did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nathan Zasler come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nathan Zasler

Neuromuscular Medicine · Richmond, VANPI 1457656969

Payments from drug & device makers

$1,371in general payments, 2019–2025

Across 75 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$199
Lundbeck LLC$154
Otsuka America Pharmaceutical, Inc.$135
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$102
Avanir Pharmaceuticals, Inc.$81
Merz North America, Inc.$76
plus $625 from 23 others

What the payments were for

Food & beverage$1,31296%
Education$594%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	11	$199
Lundbeck LLC	8	$154
Otsuka America Pharmaceutical, Inc.	7	$135
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	5	$102
Avanir Pharmaceuticals, Inc.	4	$81
Merz North America, Inc.	3	$76
Pfizer	3	$59
Lilly USA, LLC	3	$53
Supernus Pharmaceuticals, Inc.	2	$43
Azurity Pharmaceuticals, Inc.	2	$42
Axsome Therapeutics, Inc.	2	$41
Idorsia Pharmaceuticals US Inc	2	$37
Teva Pharmaceuticals USA, Inc.	2	$36
Dompe US, Inc.	2	$33
Neurocrine Biosciences, Inc.	2	$32
Neurelis, Inc.	2	$27
Mallinckrodt Hospital Products Inc.	1	$25
Sunovion Pharmaceuticals Inc.	3	$20
UCB, Inc.	1	$20
Vanda Pharmaceuticals Inc.	1	$19
Ipsen Biopharmaceuticals, Inc	1	$19
Takeda Pharmaceuticals U.S.A., Inc.	1	$18
Harrow Eye, LLC	1	$18
Collegium Pharmaceutical, Inc.	1	$16
Jazz Pharmaceuticals Inc.	1	$15
Biohaven Pharmaceuticals, Inc.	1	$15
Eisai Inc.	1	$14
Merck	1	$12
Amgen	1	$11

How this compares

Too few neuromuscular medicine providers in Virginiato place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Invega SustennaPaliperidone Palmitate	13	$49,466
TrintellixVortioxetine Hydrobromide	17	$11,815
Lacosamide	24	$8,385
MyrbetriqMirabegron	13	$7,417
Spiriva HandihalerTiotropium Bromide	11	$6,087
Aripiprazole	13	$5,877
Duloxetine Hcl	57	$3,992
Oxcarbazepine	64	$3,970
Dantrolene Sodium	16	$3,214
Atomoxetine Hcl	16	$2,770
Levetiracetam	21	$2,134
Escitalopram Oxalate	44	$1,694
Divalproex Sodium ErDivalproex Sodium	24	$1,455
Divalproex Sodium	32	$1,403
Oxybutynin Chloride ErOxybutynin Chloride	19	$1,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix	$18	$11,81517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Virginiaon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Richmond

Kathleen ThorntonRichmond$148
Eric FlorandaMidlothian$15K
Margaret BettinLynchburg$645
Francesco MichelassiCharlottesville$31

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →